Indoco Remedies Limited has informed the Exchange about Approval of Agreement to Transfer Business

Core Business DivestedStrategic Transactions View source PDF Explain this filing

INDOCO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.4%Reaction day

₹209.10

prior close

₹211.10

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.5%-0.1% vs market

Pharmaceuticals peers, median of 161sector+0.3%+1.1% vs sector

On the reaction day the stock moved 0.1 pts less than Nifty Microcap 250 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

+0.3

15m

+0.1

30m

+1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.4+1.5-0.1+0.3+1.1

Next day

+3.8+1.4+2.4+0.8+3.0

+10.5+3.0+7.5+2.2+8.3

+18.0+4.6+13.4+3.1+14.9

+9.0+4.5+4.5+3.7+5.3

+4.3+3.0+1.2+3.7+0.5

+8.1+0.6+7.5+1.0+7.1

15d

-6.4+2.9-9.3+3.0-9.4

+1.6+4.1-2.4+2.3-0.6

+12.9+10.5+2.4+6.7+6.1

+6.8+11.6-4.8+9.3-2.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 161Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Indoco Remedies Limited's Board has approved the sale of its Ophthalmic Division to Sunways (India) Private Limited for Rs. 110 Crores on a slump sale basis. The division contributed Rs. 47.79 Crores in revenue for FY 2024-25, representing just 3.2% of the company's standalone total revenue from continuing operations. The sale covers the ophthalmic business in India and 15 African territories as a going concern. The transaction is not a related party transaction and the buyer is not from the promoter group. Expected completion is around 3 months, subject to fulfilment of conditions precedent. The company states it intends to focus on core therapeutic areas.

Likely market impact

The sale is positive for Indoco as it monetises a non-core division at a reasonable valuation (roughly 2.3x revenue). The Rs. 110 crore inflow with no change in shareholding should strengthen the balance sheet and allow management to focus on higher-margin core businesses. However, the 3.2% revenue contribution means the financial impact on overall earnings will be minimal.